Phase 2 Evidence and Impact Analysis
Article 1 — Dual epitope anti-LILRB4 STAR-T cell therapy for R/R AML (PMID 42225613)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First-in-human STAR (vs. CAR) architecture targeting LILRB4 with dual epitopes; nanobody-based design is genuinely differentiated from existing AML immunotherapy approaches |
| Clinical Relevance | 8 | R/R AML has near-zero curative options; 50% ORR with no ICANS/Grade ≥3 CRS is a strong early signal; scRNA-seq resistance data immediately actionable for trial design |
| Population Reach | 5 | AML incidence ~20,000/yr in the US; globally significant but not a high-volume disease; LILRB4+ monocytic AML is a subset |
| Implementation Speed | 2 | Phase 1, n=6 evaluable; several years to Phase 3 even in best case; manufacturing complexity of STAR-T vs. CAR-T adds time |
| Evidence Strength | 5 | First-in-human Phase 1; n=6 evaluable is very small; abstract-only; mechanistic scRNA-seq adds credibility but cannot substitute for statistical power |
Key quantitative result: ORR 50% (3/6); no ICANS; no Grade ≥3 CRS — compares favorably to CAR-T in AML where CRS and ICANS are major barriers.
External validation: None yet; novel modality; preclinical dual-epitope vs. CAR-T comparisons in the same paper support superiority claim but require independent replication.
Main limitation: n=6 evaluable is critically underpowered for efficacy conclusions; abstract-only access limits full safety assessment.
Equity implications: STAR-T manufacturing is complex and centralized; access will initially be limited to academic centers; AML disproportionately affects older adults with fewer allogeneic SCT options, who stand to benefit most if safety profile holds.
Evidence Maturity (confirmed): Exploratory
Article 2 — ABBV-706 SEZ6-targeting ADC in R/R SCLC, Phase 1 (PMID 42225988)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First-in-class SEZ6-targeting ADC; SEZ6 is a novel target in neuroendocrine tumors not previously exploited therapeutically in humans |
| Clinical Relevance | 9 | R/R SCLC has <10% ORR with existing salvage; 52% ORR and 12.4-month OS in n=124 is a clinically transformative signal; RP2D determined — ready for Phase 2/3 |
| Population Reach | 6 | SCLC ~35,000 new US cases/yr; globally SCLC is ~15% of all lung cancers; high unmet need within the population |
| Implementation Speed | 4 | RP2D established; Phase 2/3 initiation plausible within 1–2 years; FDA Breakthrough Therapy designation likely being sought given signal; ADC manufacturing infrastructure exists (AbbVie) |
| Evidence Strength | 7 | Phase 1 with n=124 in primary efficacy cohort is unusually large; open-label/non-randomized limits causal inference but OS comparator to historical data is favorable; published in Nature Medicine with full peer review |
Key quantitative result: ORR 52% (65/124), median OS 12.4 months at RP2D 1.8 mg/kg Q3W; Grade ≥3 TRAEs 61% (manageable at RP2D vs. 2.5 mg/kg).
External validation: None yet from independent groups; confirmatory Phase 2/3 required; historical SCLC benchmarks (~6–8 months second-line OS, <10% ORR) provide indirect comparator.
Main limitation: Phase 1 single-arm design; no randomized comparator; sponsor (AbbVie) COI noted; Grade ≥3 TRAE rate of 61% requires careful management protocol in broader use.
Equity implications: SCLC is strongly associated with smoking history and lower socioeconomic status; if approved, cost and access equity for a historically undertreated population will be critical. ADC manufacturing costs historically high — access in LMICs will lag.
Evidence Maturity (confirmed): Exploratory — but large-cohort Phase 1 approaching Validated threshold; reclassification appropriate after confirmatory Phase 2 readout.
Article 3 — RAASi Exacerbates Anemia in Sickle Cell Disease (PMID 42224366)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Counter-intuitive finding in an established drug class; RAASi-induced anemia in SCD is biologically plausible (suppression of erythroid colony formation) but was not previously systematically quantified in this population |
| Clinical Relevance | 9 | RAASi are current standard-of-care for SCD nephropathy; finding directly affects prescribing, monitoring, and risk-benefit counseling for ~100,000 SCD patients in the US and millions globally |
| Population Reach | 7 | SCD affects ~100,000 in the US and ~25 million carriers globally; disproportionately affects Black Americans and sub-Saharan Africans — a severely underserved population |
| Implementation Speed | 8 | No new drug or technology required; monitoring change (add Hgb checks when initiating RAASi) is implementable immediately at zero cost; guideline update plausible within 12–18 months |
| Evidence Strength | 7 | Multi-cohort design (cross-sectional n=658 + two longitudinal cohorts + mechanistic mouse model); independent cohort confirmation of the same effect size strengthens causal inference despite lack of RCT; published in Blood |
Key quantitative result: β −0.46 g/dL (cross-sectional, P=0.032); −0.44 to −0.53 g/dL in longitudinal cohorts; SCD already baseline Hgb 7–9 g/dL — this magnitude is clinically significant.
External validation: Two independent longitudinal cohorts replicate cross-sectional finding; mouse model provides mechanistic confirmation; constitutes reasonable multi-level evidence short of RCT.
Main limitation: No RCT; longitudinal cohorts small (n=24, n=32); causality cannot be definitively established from observational data; indication for RAASi (nephropathy) may confound (sicker patients receive RAASi).
Equity implications: SCD disproportionately affects Black Americans and sub-Saharan Africans — populations already facing disparities in chronic disease management. This finding specifically protects a marginalized patient population from iatrogenic harm. Highly equitable in impact.
Evidence Maturity (revised): Validated — multi-cohort convergent evidence justifies this label, though RCT confirmation would be ideal.
Article 4 — CIRCULATE RCT: ctDNA-guided chemotherapy in stage II colon cancer (PMID 42225236)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ctDNA as a prognostic marker in stage II CRC is increasingly established (DYNAMIC trial series); the treatment randomization component adds novelty but is methodologically weakened by underpowering |
| Clinical Relevance | 8 | Stage II CRC adjuvant chemotherapy decisions are among the most contested in oncology; per-protocol HR 0.23 would be practice-changing if confirmed; ctDNA already entering clinical guidelines discussions |
| Population Reach | 8 | CRC is the 3rd most common cancer globally; stage II accounts for |
| Implementation Speed | 6 | ctDNA testing for stage II CRC is commercially available (Signatera, etc.); chemotherapy is available; barriers are guideline adoption and reimbursement for ctDNA testing; 1–3 years to guideline inclusion plausible |
| Evidence Strength | 6 | RCT design is strongest available for this question, but CHEMO arm n=26 means the primary endpoint was underpowered; per-protocol result is exploratory; trial closed for funding (not futility); converges with DYNAMIC-III |
Key quantitative result: ctDNA+ prognostic HR 4.28 (P<0.001); per-protocol chemotherapy HR 0.23 for recurrence (P=0.009); 3-year DFS 52% vs 87% ctDNA+ vs −.
External validation: DYNAMIC and DYNAMIC-III trials provide parallel evidence; convergent finding across independent trials strengthens credibility significantly.
Main limitation: Underpowered CHEMO arm (n=26); early trial closure; per-protocol analysis is exploratory.
Equity implications: ctDNA testing adds cost; without reimbursement equity, higher-resource patients will access ctDNA-guided care first. Low-income and rural populations may be under-tested. Race/ethnicity data not reported in abstract.
Evidence Maturity (confirmed): Validated — convergent RCT signal across multiple trials, though confirmatory power is incomplete.
Article 5 — cfDNA methylation biomarkers for ALS diagnosis and progression (PMID 42222887)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First application of multimodal cfDNA methylation profiling to ALS diagnosis and progression monitoring; no validated blood biomarker exists for ALS currently |
| Clinical Relevance | 7 | ALS diagnostic delay of 12+ months is a major clinical problem; AUC 0.91 at near-100% specificity would meaningfully accelerate diagnosis if validated at scale; also enables clinical trial enrichment |
| Population Reach | 4 | ALS prevalence |
| Implementation Speed | 3 | EM-seq of 4 million CpG sites is technically demanding and far from clinical-grade assay readiness; n=61 requires large-scale external validation before any clinical application |
| Evidence Strength | 5 | Case-control with internal validation; n=61 is small; no independent external cohort; assay complexity is high; full text available adds credibility |
Key quantitative result: AUC 0.91 ± 0.10; sensitivity ~70% at ~100% specificity; methylation correlates with CSF neurofilament (progression marker).
External validation: None yet; internal validation only; large-scale prospective external validation required.
Main limitation: n=61 total; single-center; EM-seq technically complex; clinical translation requires significant assay simplification and prospective longitudinal validation.
Equity implications: ALS is relatively rare and affects a broadly distributed population; clinical translation barriers (assay cost, specialized lab) may limit access initially to academic centers.
Evidence Maturity (confirmed): Exploratory
Article 6 — BBB Senescence Unit Drives AD Pathology — snRNA-seq (PMID 42223825)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | "BBB Senescence Unit" concept organizing 4 cell types into a coordinated pathological structure is a novel mechanistic framework; SPP1-CD44 axis as hub is new and therapeutically actionable |
| Clinical Relevance | 5 | Mechanistic discovery in human brain tissue; CSF proteomics validation bridges to clinical relevance; but no treatment data and therapeutic application is several steps away |
| Population Reach | 9 | Alzheimer's affects 50+ million globally; any validated mechanistic insight with therapeutic implications has enormous potential reach |
| Implementation Speed | 2 | Preclinical/mechanistic stage; SPP1 inhibitors exist investigationally but AD therapeutic development timeline is historically 10–15 years |
| Evidence Strength | 6 | snRNA-seq on 75 human brains is reasonable for this modality; CSF proteomics cross-validation adds independent data layer; abstract-only access limits full assessment; Molecular Neurobiology is solid but not top-tier |
Key quantitative result: SPP1 identified as hub gene correlated with all AD pathological scores; validated in independent CSF proteomics dataset.
External validation: CSF proteomics provides independent cross-tissue validation; published datasets used for correlation strengthen but cannot substitute for functional validation.
Main limitation: Observational/correlative; no functional intervention data in humans; abstract-only; causal directionality of the senescence unit requires experimental confirmation.
Equity implications: AD disproportionately affects women and, in late stages, minority populations with limited access to specialist care; any therapeutic advance could have high equity impact if priced and distributed accessibly.
Evidence Maturity (confirmed): Exploratory
Article 7 — TP53-deficient AML secretome suppresses T-cell engagers via TGF-β1 (PMID 42225967)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Mechanistic identification of TGF-β1 as the specific mediator of BiTE resistance in TP53-deficient AML is novel and immediately actionable |
| Clinical Relevance | 5 | In vitro and primary cell data only; no patient outcome data; but directly relevant to combination trial design in TP53-AML where BiTE activity is clinically disappointing |
| Population Reach | 4 | TP53-mutant AML is 10–15% of de novo, 25% of therapy-related AML — an important but limited subpopulation |
| Implementation Speed | 3 | Preclinical; combination trial with TGF-β inhibitor + AMG 330 or similar would need Phase 1 design; 3–5 year timeline to first human data |
| Evidence Strength | 5 | In vitro co-culture + primary AML samples; mechanistically rigorous but limited to cellular models; published in Leukemia (high-quality journal); abstract-only |
Key quantitative result: TGF-β1 identified as key mediator; T cells adopt senescent transcriptional profile in TP53-KD co-cultures (specific quantitative effects not extractable from abstract).
External validation: None; in vitro only.
Main limitation: No in vivo or clinical data; in vitro results may not translate to patient TME complexity.
Equity implications: TP53-mutant AML often arises in therapy-related settings (prior chemotherapy); this population includes cancer survivors who are already medically complex.
Evidence Maturity (confirmed): Exploratory
Article 8 — RFX7 suppresses Myc-dependent lymphomagenesis (PMID 42225953)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | RFX7 as a novel B-cell tumor suppressor limiting Myc is a genuinely new finding; establishes RFX7-Myc and RFX7-AID axes as new lymphoma biology |
| Clinical Relevance | 4 | Mouse model with human genomic correlation only; DLBCL prognostic correlation is suggestive but causal link to treatment outcomes not established |
| Population Reach | 5 | DLBCL is the most common lymphoma (~25,000 US cases/yr); RFX7 mutations found across CLL, DLBCL, FL — multi-disease |
| Implementation Speed | 2 | Purely mechanistic; Myc inhibition strategies have been a major research challenge for decades; RFX7-targeted approaches are years from clinical application |
| Evidence Strength | 5 | Rigorous mouse genetics + human genomic correlation; Nature Immunology quality is very high; but non-human dominant with correlation (not causation) in human data |
Key quantitative result: Low RFX7 mRNA correlates with worse DLBCL prognosis (quantitative effect size not extractable from abstract).
External validation: Human genomic datasets provide cross-species validation; independent cohort confirmation of prognostic correlation strengthens the finding.
Main limitation: No human treatment data; Myc has been a notoriously difficult therapeutic target; RFX7 loss-of-function is a loss, not a gain — harder to drug.
Equity implications: DLBCL treatment outcomes vary by access to R-CHOP and transplant; mechanistic advances benefiting DLBCL patients with high-risk molecular features could disproportionately help those currently under-served by standard therapy.
Evidence Maturity (confirmed): Exploratory
Article 9 — Morphological lymphocyte counts as prognostic markers in aggressive ATL (PMID 42225671)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CBC-based prognostication in hematologic malignancy is an established approach; applying it specifically to the normal vs. abnormal lymphocyte distinction in ATL is new but incremental |
| Clinical Relevance | 7 | Immediately applicable prognostic tool at zero additional cost; adds to existing scoring systems for treatment stratification in a rare but lethal disease |
| Population Reach | 3 | ATL is endemic to southwestern Japan, Caribbean, and parts of South America/Africa; global incidence ~1,000–3,000/yr; limited population reach but high unmet need within endemic regions |
| Implementation Speed | 9 | CBC is universally available; no new technology, cost, or infrastructure required; implementable by clinicians reading this paper today |
| Evidence Strength | 7 | Prospective nationwide registry, n=638, 152 institutions; multivariate analysis; well-powered for a rare disease; Blood Cancer Journal is credible |
Key quantitative result: Low normal lymphocyte (<860/μL) independently predicts OS (P<0.001); high abnormal (>15,000/μL) independently predicts PFS.
External validation: Multi-institutional (152 centers) provides inherent generalizability within Japan; external validation in Caribbean/endemic populations needed.
Main limitation: ATL population predominantly Japanese; relevance to HTLV-1-endemic populations in other regions requires separate validation; CBC morphological differential requires experienced lab.
Equity implications: ATL disproportionately affects populations in resource-limited settings (Caribbean, HTLV-1 endemic regions); a CBC-based tool is uniquely equitable since it requires no expensive diagnostics.
Evidence Maturity (confirmed): Validated
Article 10 — ThalP hybrid ML model for thalassemia classification from CBC (PMID 42220235)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Hybrid stacking of SVM+LR+XGBoost is methodologically sound but not novel; application to thalassemia subtyping from CBC parameters has been explored before though this combination is new |
| Clinical Relevance | 5 | Thalassemia misclassification affects treatment planning; CBC-only ML classification could reduce reliance on expensive genetic testing in resource-limited settings |
| Population Reach | 7 | Thalassemia affects ~300,000 births annually globally; high prevalence in South/Southeast Asia, Mediterranean, Middle East — predominantly resource-limited settings |
| Implementation Speed | 5 | CBC data is universally available; model implementation requires software deployment but no new hardware; training data on synthetic samples limits confidence in deployment readiness |
| Evidence Strength | 4 | External validation on n=349 real patients is meaningful; but training on synthetic data (n=1534 generated samples) weakens generalizability claims; single-center validation |
Key quantitative result: 83.1% accuracy, macro-F1 0.80 on n=349 external real-world patients.
External validation: Single-center external validation only; no independent multi-site validation.
Main limitation: Training data predominantly synthetic; single-center Turkish external validation may not generalize to other endemic regions (e.g., Southeast Asia, Africa) where thalassemia phenotypes differ.
Equity implications: Designed for resource-limited settings where genetic confirmation is inaccessible; high equity potential if validated in diverse populations.
Evidence Maturity (confirmed): Validated (within stated population)
Article 11 — Computer vision model for inflammatory arthritis detection from smartphone photos (PMID 42226010)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Smartphone-based CV detection of synovitis has been explored in research settings; this is one of the larger prospective clinical validations; ConvNeXt-V2 architecture is current state-of-art |
| Clinical Relevance | 7 | Inflammatory arthritis diagnosis delay is a major clinical and disability burden; non-specialist access via smartphone could reduce time-to-treatment in LMIC and primary care settings |
| Population Reach | 8 | RA and inflammatory arthritis affect ~1% of global population; non-specialist screening tool relevant to billions in underserved healthcare settings |
| Implementation Speed | 6 | Smartphone apps can be deployed rapidly; regulatory pathway for AI diagnostic tools varies by country; India-specific training requires external validation for other populations |
| Evidence Strength | 6 | Large prospective cohort (n=1112); multi-group stability testing; AUROC 0.852 is solid but not exceptional; single-center Indian cohort limits external validity |
Key quantitative result: AUROC 0.852, accuracy 0.79, sensitivity 0.76, specificity 0.80.
External validation: Not yet validated outside India; single center.
Main limitation: Single-center Indian cohort; ground truth is specialist clinical assessment (not biopsy); generalizability to other ethnic/demographic groups uncertain.
Equity implications: Explicitly designed for underserved populations lacking rheumatology access; India and LMICs are the primary beneficiaries. Equity implications are strongly positive if validated cross-culturally.
Evidence Maturity (confirmed): Validated (within stated population)
Article 12 — Deep learning for acute ischemic stroke detection on NCCT (PMID 42225843)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI-assisted stroke detection on NCCT is an active and somewhat crowded field; multi-reader crossover design is methodologically rigorous but the finding is incremental |
| Clinical Relevance | 7 | Stroke time-to-diagnosis is critical; +5.38% accuracy improvement for non-radiologist readers in emergency settings is clinically meaningful for a time-sensitive condition |
| Population Reach | 9 | Stroke is 2nd leading cause of death globally; ~800,000 US cases/yr; NCCT is the universal first-line imaging modality |
| Implementation Speed | 5 | AI NCCT tools are already in commercial deployment (see Viz.ai, RapidAI); this adds evidence for the non-radiologist benefit; regulatory clearance pathway exists |
| Evidence Strength | 6 | n=917, multi-reader crossover randomized design is rigorous; retrospective case selection limits generalizability; industry COI (SK Inc. C&C) noted |
Key quantitative result: +3.60% overall accuracy improvement (P<0.001); +5.38% for non-radiologist physicians; standalone AI AUROC 0.8144.
External validation: Multi-reader design provides internal validation across expertise levels; no external institutional validation reported.
Main limitation: Retrospective; single-institution case set; industry COI; improvement is modest (+3.60%) at overall level though clinically meaningful in non-specialist subgroup.
Equity implications: Benefit concentrated in non-specialist readers — most relevant for rural/community hospitals and LMICs where specialist coverage is limited.
Evidence Maturity (confirmed): Validated
Article 13 — Oral semaglutide 25mg vs orforglipron 36mg indirect comparison (PMID 42225305)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Indirect treatment comparisons between competing drugs are common; the specific comparison is new given orforglipron's recent trial data, but methodology is not novel |
| Clinical Relevance | 5 | Relevant for prescribers choosing between oral GLP-1 agents; −3.2% differential weight loss and GI tolerability difference are clinically meaningful if real, but ITC methodology substantially limits confidence |
| Population Reach | 8 | Obesity affects 40%+ of US adults; oral GLP-1 agents represent a massive and growing therapeutic category |
| Implementation Speed | 5 | Both agents are in or near approval; prescribing guidance could inform immediate formulary decisions; however, head-to-head RCT needed before definitive adoption |
| Evidence Strength | 3 | ITC is methodologically inferior to direct RCT; Novo Nordisk sponsorship introduces commercial bias; population adjustment may not fully account for trial differences; no individual patient data |
Key quantitative result: −3.2 percentage points greater weight loss (95% CI −5.9 to −0.4); GI AE discontinuation OR 13.9 favoring semaglutide.
External validation: Not applicable (no independent replication of an ITC).
Main limitation: Not a head-to-head RCT; sponsor COI (Novo Nordisk makes semaglutide); ITC cannot control for unmeasured baseline differences.
Equity implications: Oral formulation access (vs. injectable) is important for patients with needle phobia or limited care access; however, GLP-1 drug costs remain a major equity barrier globally.
Evidence Maturity (confirmed): Exploratory
Article 14 — Cardiometabolic multimorbidity prevalence in Iran — STEPS 2021 (PMID 42225676)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Benchmarking study; methodology (WHO STEPS) is standardized; COVID-19 as a determinant is the only novel signal |
| Clinical Relevance | 4 | Provides national prevalence data; limited direct patient-care implications; more relevant to public health planning |
| Population Reach | 6 | Iran population ~88 million; findings potentially generalizable to neighboring MENA countries |
| Implementation Speed | 5 | Epidemiological data can inform policy immediately but behavioral change/intervention implementation is slower |
| Evidence Strength | 6 | n=16,453 nationally representative sample; WHO STEPS methodology is standardized; MI/stroke self-report is a limitation |
Key quantitative result: 14.43% cardiometabolic multimorbidity prevalence (95% CI 13.67–15.22).
External validation: WHO STEPS methodology provides cross-country comparability.
Main limitation: Cross-sectional; MI/stroke self-reported; COVID-19 link is cross-sectional correlation only.
Equity implications: Identifies higher burden in rural populations and those with lower education; COVID-19 hospitalization link may flag a post-COVID cardiometabolic risk population needing surveillance.
Evidence Maturity (confirmed): Validated (descriptive)
Article 15 — 211At-CD45 RIT conditioning for HSPC gene therapy in NHPs (PMID 42224345)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Alpha-emitter RIT conditioning avoiding TBI toxicity is a high-novelty approach with major implications for gene therapy safety and accessibility |
| Clinical Relevance | 3 | NHP study only; cap applied per non-human rule; direct patient application is 5–10 years away |
| Population Reach | 5 | Sickle cell disease, thalassemia, and other HSC diseases collectively affect millions globally; conditioning toxicity is a major barrier to gene therapy access |
| Implementation Speed | 1 | NHP data, n=4; significant regulatory, manufacturing, and radiopharmaceutical infrastructure barriers |
| Evidence Strength | 4 | n=4 NHPs is very small; 18-month follow-up is encouraging; non-human cap applied; published in Blood |
Key quantitative result: Up to 70% combined gene-editing efficiency in blood at >18 months; no non-hematopoietic toxicity.
External validation: None; single NHP study.
Main limitation: NHP n=4; radiopharmaceutical (211At) production and delivery logistics are complex; IND application and first-in-human timeline is uncertain.
Equity implications: Current myeloablative conditioning toxicity is a major access barrier for gene therapy in SCD (often young Black patients). A safer conditioning regimen could dramatically expand eligibility to patients not fit for TBI.
Evidence Maturity (confirmed): Exploratory
Article 16 — Discordant ctDNA/tumor fraction dynamics in mCRC — dilution phenomenon (PMID 42225541)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dilution phenomenon in ctDNA monitoring is a previously recognized but undercharacterized phenomenon; this provides the clearest quantitative characterization to date |
| Clinical Relevance | 6 | Directly relevant to clinical interpretation of ctDNA panels in mCRC; caution warranted but limited by small event count |
| Population Reach | 6 | Metastatic CRC is common (~150,000 US patients in treatment); ctDNA monitoring is increasingly standard |
| Implementation Speed | 5 | Requires only reporting practice change (add absolute ctDNA to tumor fraction reports); no new technology |
| Evidence Strength | 4 | Retrospective; n=55 patients, 7 events in 5 patients; underpowered; exploratory |
Key quantitative result: Elevated absolute ctDNA predicts dilution OR 3.25 (P=0.025); 7 dilution events in 5 patients.
Main limitation: Very small event count (n=7 events); single-center retrospective; findings are hypothesis-generating.
Evidence Maturity (confirmed): Exploratory
Article 17 — CBX4 drives AML-M5 via HDAC-mediated Runx1 suppression (PMID 42225948)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CBX4 as an AML-M5 driver is a new mechanistic finding; HDAC-Runx1 connection in monocytic AML adds to known epigenetic dysregulation pathways |
| Clinical Relevance | 3 | Zebrafish/human expression correlation only; non-human dominant; clinical translation is speculative |
| Population Reach | 3 | AML-M5 is a subtype (~5–10% of AML); limited reach within an already rare disease |
| Implementation Speed | 2 | Very early stage; HDAC inhibitors exist but CBX4-specific targeting is undeveloped |
| Evidence Strength | 4 | Zebrafish transgenic + human expression data; mixed species; medium confidence classification; abstract-only |
Evidence Maturity (confirmed): Exploratory
Article 18 — cGAS-STING in neuroinflammation — JCI review (PMID 42222892)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Synthesizes existing knowledge with noncanonical cGAS-STING nuclear functions as newer content; review rather than primary discovery |
| Clinical Relevance | 4 | Useful pathway summary; pharmacological inhibitor catalogue is actionable for drug developers but no new clinical data |
| Population Reach | 8 | AD/neurodegeneration affects tens of millions globally |
| Implementation Speed | 2 | Review of preclinical data; clinical inhibitor trials are early-stage |
| Evidence Strength | 4 | Review article; no new primary data; JCI editorial standards add credibility |
Evidence Maturity (confirmed): Exploratory
Article 19 — Dementia landscape in India — narrative review (PMID 42222939)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Narrative review synthesizing existing data; no new analyses |
| Clinical Relevance | 3 | Epidemiological context; no new clinical interventions |
| Population Reach | 8 | India has 1.4 billion people; dementia is a global health priority |
| Implementation Speed | 4 | Could inform policy and research funding priorities |
| Evidence Strength | 3 | Narrative review; not systematic; abstract-only |
Evidence Maturity (confirmed): Exploratory
Article 20 — Gene therapy attitudes in AATD patients (PMID 42224713)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Patient preference studies are common; AATD-specific gene therapy attitudes are novel for this rare disease |
| Clinical Relevance | 4 | Useful for trial design and informed consent frameworks; not directly patient care-changing |
| Population Reach | 3 | AATD affects ~100,000 in the US; rare disease |
| Implementation Speed | 6 | Survey findings can immediately inform trial recruitment and education strategies |
| Evidence Strength | 5 | n=1112 (large for a rare disease survey); convenience sample via AlphaNet; survey methodology limitations |
Evidence Maturity (confirmed): Exploratory
Article 21 — ADCs in hematologic malignancies — review (PMID 42225588)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Comprehensive but synthesizing known landscape |
| Clinical Relevance | 5 | Useful clinical reference; contextualizes treatment decisions |
| Population Reach | 6 | Hematologic malignancies collectively affect hundreds of thousands annually |
| Implementation Speed | 5 | Reference document; no new actionable recommendations |
| Evidence Strength | 4 | Review; no primary data |
Evidence Maturity (confirmed): Validated (synthesizes existing approved data)
Article 22 — AML Integrated Comorbidity-ECOG-Age criteria (PMID 42216561)
Title-only classification; abstract unavailable after 3 attempts. All scores capped per low-confidence classification protocol.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 2 | Cannot assess |
| Clinical Relevance | 2 | Cannot assess |
| Population Reach | 3 | AML is a significant hematologic malignancy; topic is clinically relevant |
| Implementation Speed | 2 | Cannot assess |
| Evidence Strength | 1 | No abstract available; title-only |
Evidence Maturity: Cannot determine — closed as LOW.